Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay is a better alternative than Sanger, karyology, or Southern blot and is relevant for:
- Monoclonal antibodies & recombinant proteins: clone selection and genetic stability testing.
- Cell therapy: lot release testing
- Targeted Locus Amplification (TLA)
- Cultivated meat: clone selection and genetic stability testing.
Prof. Nicole Borth, PhD
Department of Biotechnology
Universität für Bodenkultur (BOKU)
Vienna, Austria
Colette Côté, PhD
Chief Scientific & Portfolio Officer
PathoQuest
Wayne, Pennyslvania
Chief Scientific & Portfolio Officer
PathoQuest
Wayne, Pennyslvania
Dan Fordham
Director, Strategic Product Management
Oxford Nanopore Technologies
Oxford, England